Overture Life announced a $20.6 million strategic round, bringing its total funding to $57 million from leading industry investors, to support additional clinical research and product development designed to make IVF affordable to more people.
The company also announced a newly achieved CLIA (Clinical Laboratory Improvement Amendments) license in the US to meet federal clinical laboratory standards for m|z, its AI-based and non-invasive metabolomic test for embryo selection. These latest milestones reinforced Overture’s commitment to showing scientific rigor, securing regulatory support, and prioritizing patient safety. This also paves the way for the launch of DaVitri, which is an advanced embryology platform that automates egg freezing (vitrification) and embryo warming under reproducible, data-driven protocols.
This strategic funding round was supported by Overwater Ventures, GV (formerly Google Ventures), and Khosla Ventures. The funding reflects a deep conviction in Overture’s science-led goal: to expand fertility access by making IVF labs more reproducible, efficient, and ultimately less cost-intensive.
IVF has been inaccessible for too many people, with inefficiencies increasing costs. And since 2017, Overture modernized the core technology involved in IVF with proprietary software, robotics, microfluidics and scientific validation, documented in peer-reviewed publications, scientific presentations, and two healthy live births resulting from the use of its technology.
Through its newest platform, DaVitri addresses essential lab steps that rely on manual precision. And by standardizing these procedures with precise timing and controlled cryoprotectant exposure, DaVitri has shown improved oocyte survival rates in early clinical evaluations, reducing repeated IVF cycles that can drain resources and emotional energy. Plus, its streamlined, gentler freezing process helps clinics maintain consistent lab results, enabling embryologists to handle more cycles without compromising quality.
KEY QUOTES:
“This new funding allows us to accelerate our expansion of IVF capabilities and demonstrates the value of operating within a CLIA-licensed laboratory environment, highlighting not only our technological leadership but also our commitment to the highest standards of clinical validation. DaVitri has already shown potential to significantly increase clinical throughput while ensuring reproducibility in critical freezing and warming processes, allowing embryologists to prioritize personalized patient care. Our approach is rigorous and evidence-based because we understand how deeply personal this journey is for families.”
Hans Gangeskar, CEO of Overture Life
“Automation and standardization in the embryology lab is an exciting step towards optimizing efficiency and efficacy in IVF. It allows us to deliver consistent and excellent care, while still giving us the flexibility to fine-tune protocols for our patients. We’re very excited about the potential to serve more patients by increasing lab capacity without sacrificing quality.”
Serena H. Chen, MD, a Reproductive Endocrinologist at CCRM Fertility of NJ
“Fertility intersects healthcare, economics, and the most personal of human wishes. Women have long faced irreversible biological timelines, and by making egg freezing cheaper, easier, and more clinically effective and predictable, it allows women and families to regain choice and opportunity. Overture’s platform provides a precise alternative that can run more cycles successfully, enabling women to freeze their eggs or pursue IVF on their own terms and timelines. By fitting the embryology protocols into a compact, desk-sized system, Overture is reinventing egg freezing and IVF for a better patient experience and strong, clinically reproducible outcomes with proven science.”
Kristina Simmons, Founder and Managing Partner at Overwater Ventures
